Kura Oncology (NASDAQ:KURA) Stock Rating Lowered by StockNews.com

Kura Oncology (NASDAQ:KURA) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

KURA has been the topic of a number of other reports. JMP Securities raised their price objective on shares of Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research note on Wednesday, January 31st. Mizuho assumed coverage on shares of Kura Oncology in a research note on Friday, December 22nd. They issued a “buy” rating and a $26.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Wednesday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $28.28.

Kura Oncology Stock Performance

NASDAQ KURA opened at $18.59 on Monday. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -8.94 and a beta of 0.85. The company has a 50 day moving average of $20.93 and a 200-day moving average of $15.08. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.01. During the same quarter last year, the business posted ($0.49) EPS. On average, equities analysts forecast that Kura Oncology will post -2.35 earnings per share for the current fiscal year.

Insider Transactions at Kura Oncology

In related news, SVP Thomas James Doyle sold 2,318 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $41,260.40. Following the transaction, the senior vice president now owns 48,093 shares in the company, valued at approximately $856,055.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Kura Oncology news, SVP Thomas James Doyle sold 2,318 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $41,260.40. Following the completion of the sale, the senior vice president now owns 48,093 shares of the company’s stock, valued at approximately $856,055.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Kathleen Ford sold 1,496 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the sale, the chief operating officer now directly owns 21,602 shares of the company’s stock, valued at approximately $384,515.60. The disclosure for this sale can be found here. Insiders have sold 96,919 shares of company stock worth $1,946,415 in the last ninety days. Insiders own 5.60% of the company’s stock.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in KURA. State Street Corp increased its position in Kura Oncology by 44.1% during the 3rd quarter. State Street Corp now owns 4,368,763 shares of the company’s stock worth $59,677,000 after purchasing an additional 1,337,149 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Kura Oncology by 35.1% during the third quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock worth $39,891,000 after acquiring an additional 1,136,044 shares in the last quarter. BlackRock Inc. boosted its stake in Kura Oncology by 14.7% during the second quarter. BlackRock Inc. now owns 6,157,402 shares of the company’s stock worth $65,145,000 after acquiring an additional 788,095 shares in the last quarter. BVF Inc. IL boosted its stake in Kura Oncology by 9.5% during the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock worth $106,027,000 after acquiring an additional 642,245 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Kura Oncology in the first quarter valued at $7,930,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.